Novel compositions and methods of treatment

Low molecular weight oligosaccharides act as TLR4 antagonists, addressing the ineffectiveness of current sepsis and AMD treatments by inhibiting inflammatory biomarkers and angiogenesis, offering therapeutic benefits for sepsis, ocular inflammation, and AMD.

JP7594268B2Active Publication Date: 2024-12-04AYUVIS RES INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2020007053
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-03-30
Filing Date
2020-01-20
Publication Date
2024-12-04
Estimated Expiration
2037-03-30

AI Technical Summary

Technical Problem

Current treatments for sepsis, septic shock, ocular inflammation, and age-related macular degeneration are not effective, particularly for immunocompromised and elderly patients, and there is a need for more effective anti-inflammatory and anti-angiogenic therapies.

Method used

Development of low molecular weight, water-soluble oligosaccharides that act as Toll-like receptor 4 (TLR4) antagonists, inhibiting inflammatory biomarkers and angiogenesis, formulated into pharmaceutical compositions for parenteral, topical, and ophthalmic applications.

Benefits of technology

The compounds effectively inhibit inflammatory cytokines, reduce lesion size in ocular neovascularization, protect against sepsis-induced death, and demonstrate broad-spectrum antibacterial activity, providing therapeutic benefits for sepsis, ocular inflammation, and AMD.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594268000025
    Figure 0007594268000025
  • Figure 0007594268000026
    Figure 0007594268000026
  • Figure 0007594268000027
    Figure 0007594268000027
Patent Text Reader

Abstract

To provide methods for the treatment of an inflammation caused by polymicrobial infections, and sepsis and severe sepsis, SIRS and septic shock.SOLUTION: The present invention provides a composition containing chitin and chitosan derivatives as an active ingredient.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] cross reference This application claims the benefit of U.S. Provisional Patent Application No. 62 / 315,144, filed March 30, 2016, which is incorporated herein by reference.

[0002] The present invention relates to novel products, their variants, pharma- ceutically acceptable salts and prodrugs, and the medical use of such compounds for the treatment and / or management of sepsis, septicemia, septic shock, ocular infections, ocular inflammation, ocular neovascularization, rheumatoid arthritis (RA), atherosclerosis, inflammatory bowel diseases (IBD), asthma, chronic obstructive pulmonary disease, febrile syndromes, cachexia, psoriasis, autoimmune diseases, heart disease, retinoblastoma, cancer, and / or any disorder associated with inflammation, immunomodulation and microbial infection. [Background technology]

[0003] Sepsis has been identified as one of the five diseases with the highest hospitalization costs in the United States. The outcome of sepsis is particularly unfavorable in elderly, immunocompromised, and critically ill patients. In addition to its clinical challenges, the treatment of sepsis imposes a large economic burden on healthcare systems worldwide. Over 900,000 cases are estimated to occur annually in the United States alone, with total annual costs estimated at approximately $26 billion nationwide. Currently, the treatment of sepsis typically involves one of three broad adjunctive (non-antibiotic) therapeutic approaches: (1) improved supportive care (i.e., oxygen therapy / ventilation strategies, fluid optimization / use of vasopressors, early goal-directed therapy), (2) targeting bacterial virulence factors (i.e., antiendotoxin antibodies, endotoxin removal columns), or (3) targeting host response factors (i.e., corticosteroids, anticytokine drugs, anticoagulants). However, current therapies are not completely effective in patients suffering from sepsis and septic shock. These treatments are even less effective in immunocompromised and elderly patients. Summary of the Invention [Means for solving the problem]

[0004] The present invention overcomes the shortcomings of the prior art by providing low molecular weight water-soluble oligosaccharides (compounds 1-3) that exhibit antagonist activity against TLR4, useful for treating inflammatory conditions such as the pathogenesis of age-related macular degeneration (AMD). Such inflammatory conditions include, but are not limited to, ocular inflammatory diseases and choroidal neovascularization. Specifically, the present invention relates to compounds (4, 15, 16 and 25) for the treatment of inflammation. In some embodiments, the inflammation is caused by polymicrobial infection. In some embodiments, the compounds find use in the treatment of sepsis and severe sepsis, SIRS and septic shock.

[0005] The compounds of the present invention have been unexpectedly found to have excellent anti-inflammatory activity in inhibiting inflammatory biomarkers such as TNF-α, IL-1β and IL-6 in LPS-induced human monocyte assays and producing the anti-inflammatory cytokine IL-10 in monocytes. The compounds of the present invention protected mice from both lethal gram-negative sepsis and lethal polymicrobial sepsis caused by E. coli in a cecal ligation and puncture model. Thus, the present disclosure provides a method of inhibiting inflammatory biomarkers, such as but not limited to TNF-α, IL-1β and IL-6, in LPS-induced human monocyte assays by administering the compounds disclosed herein to a patient in need thereof. Furthermore, the present disclosure provides a method of protecting mice from lethal gram-negative sepsis caused by E. coli by administering the compounds disclosed herein to a patient in need thereof. The compounds of the present invention have also been unexpectedly found to have broad spectrum antibacterial activity against both Gram-positive bacteria (methicillin-sensitive and methicillin-resistant Staphylococcus aureus), Gram-negative bacteria (E. coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae), and fungi (Candida albicans) found primarily in burn and septic wounds. Thus, the present disclosure provides a method of treating infections caused by both Gram-positive bacteria (methicillin-sensitive and methicillin-resistant Staphylococcus aureus), Gram-negative bacteria (E. coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae), and fungi (Candida albicans) by administering the compounds disclosed herein to a patient in need thereof. The compounds of the present invention have also been unexpectedly found to inhibit and eradicate biofilms formed by Staphylococcus aureus. Thus, the present disclosure provides methods of inhibiting or eradicating biofilms formed by microorganisms, such as, but not limited to, Staphylococcus aureus, by contacting a surface with a compound disclosed herein.The compounds of the present invention also showed excellent in vivo efficacy in protecting mice against cecal ligation and puncture (CLP)-induced death and organ dysfunction. The compounds of the present invention were also unexpectedly found to have excellent activity against HMGB1-induced inflammation in mouse macrophages, reduced VEGF expression in retinal pigment epithelial cells (ARPE-19), and daily intraperitoneal injection of the compounds could reduce the average size of CNV lesions to about 60% of the average size of CNV lesions in control mice treated with vehicle alone. Thus, the present disclosure provides a method of protecting a subject in need of such treatment from infection or infection-related disorders by treating the subject with a compound disclosed herein.

[0006] The foregoing brief summary broadly describes the features and technical advantages of certain embodiments of the present invention. Additional features and technical advantages are described in the following detailed description of the invention. The novel features believed to be characteristic of the present invention will be better understood from the detailed description of the invention when considered in conjunction with any accompanying drawings. However, the drawings provided herein are intended to help explain the invention or aid in developing an understanding of the invention, and are not intended to define the scope of the invention. That is, the present invention relates to the following: 1. Formula (VI) JPEG0007594268000001.jpg39170 (in the formula, n=0~1 R=benzyl, substituted benzyl, R1=COCH3, N-dimethylmaleimide, R2 = cyclohexyl, p-nitrophenyl, piperidine nitroxy, piperidine-N-hydroxyl, p-methoxyphenyl) or a pharma- ceutical composition comprising a compound of formula (I) or a pharma- ceutical acceptable salt thereof; 2. The composition according to claim 1, which is formulated into a sterile injectable aqueous or oily suspension, or a sterile topical gel, ointment or aqueous spray; 3. The composition according to claim 1, further comprising at least one of an anti-inflammatory agent or an antibacterial agent. 4. Use of the composition according to claim 1 for treating sepsis, septic shock, toxemia, burn or wound infection, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (VI) or a pharma- ceutically acceptable salt thereof, thereby treating said subject. 5. The use according to 4 above, wherein administering comprises administering to a patient in need thereof a pharmaceutical composition comprising about 5.0 mg to about 100 mg of a compound of formula (VI) or a pharma- ceutically acceptable salt thereof, thereby treating said patient; 6. The use according to 4 above, wherein administering comprises administering to a patient in need thereof a pharmaceutical composition comprising about 10.0 mg to about 1000 mg of a compound of formula (VI) or a pharma- ceutically acceptable salt thereof, thereby treating said patient; 7.Formula (V) JPEG0007594268000002.jpg41170 (in the formula, n=0~5 R=H, C(O)CH3, C(O)-Piperidine nitroxy, C(O)-Piperidine N-hydroxyl R1=alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl, piperidine nitroxyl, piperidine N-hydroxyl) or a pharma- ceutical composition comprising a compound of formula (I) or a pharma- ceutical acceptable salt thereof; 8. The composition according to claim 7, which is formulated into a sterile injectable aqueous or oily suspension, or a sterile topical gel, ointment or aqueous spray; 9. The composition according to claim 7, further comprising at least one of an anti-inflammatory agent or an antibacterial agent. 10. Use of the composition according to claim 7 for treating sepsis, septic shock, toxemia, burns or wound infections, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (V) or a pharma- ceutically acceptable salt thereof; 11. The use according to the above 10, wherein the pharmaceutical composition comprises about 5.0 mg to about 100 mg of the compound of formula (V) or a pharma- ceutically acceptable salt thereof for a patient in need thereof, thereby treating the patient, or the pharmaceutical composition comprises about 10.0 mg to about 1000 mg of the compound of formula (V) or a pharma- ceutically acceptable salt thereof for a patient in need thereof, thereby treating the patient; 12.Formula (II) JPEG0007594268000003.jpg41170 (wherein n=5 to 7) or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable vehicle comprising PLA or PLGA microparticles. 13. The composition according to claim 12, which is formulated into a sterile injectable aqueous or oily suspension or as a sterile topical ophthalmic solution. 14. The composition according to claim 12, further comprising at least one of an anti-inflammatory agent or an antibacterial agent. 15. Use of a composition of formula (II) in a therapeutically effective amount of a pharmaceutical composition or a pharma- ceutically acceptable salt thereof for treating ocular neovascularization, ocular inflammation; 16. The use according to 15 above, wherein the pharmaceutical composition comprises about 5.0 mg to about 100 mg of the compound of formula (II) or a pharma- ceutically acceptable salt thereof for a patient in need thereof, thereby treating the patient, or the pharmaceutical composition comprises about 10.0 mg to about 1000 mg of the compound of formula (II) or a pharma- ceutically acceptable salt thereof for a patient in need thereof, thereby treating the patient. [Brief description of the drawings]

[0007] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. [Figure 1]1 is a graph showing the results of evaluation of the TLR4 antagonist compound 1 of the present invention in mouse endotoxemia and sepsis models, showing that compound 1 protects mice from lethal Gram-negative sepsis caused by Escherichia coli. [Diagram 2] 1 is a graph showing the results of evaluation of a TLR4 antagonist of the present invention, Compound 4, in a cecal ligation and puncture (CLP) model, demonstrating that Compound 4 protects mice from CLP-induced polymicrobial sepsis and mortality. [Diagram 3] Upon treatment with compound 4, histopathology of major organs demonstrates that the compound of the present invention reverses major pathological changes, with tissues resembling the sham group. [Figure 4] It was demonstrated that compound 4 of the present invention effectively down-regulates inflammatory cytokines in vivo in CLP mice. [Diagram 5] FIG. 1 is a graph showing the results of evaluation of compounds 15 and 25 of the invention in a cecal ligation and puncture (CLP) model, showing that both compounds protect mice from CLP-induced polymicrobial sepsis and mortality. [Figure 6] 1 shows the evaluation of the TLR4 antagonist compound 2 of the present invention in a laser-induced CNV mouse model of wet AMD. Compound 2 reduced choroidal neovascularization by approximately 60% compared to the positive control. [Figure 7] A series of compounds of the present invention are shown to effectively bind to the TLR4 receptor and not to the TLR2 receptor. [Figure 8(AB)] demonstrate that compounds of the invention inhibited LPS-induced production of inflammatory mediators in human monocytes. [Figure 9] We demonstrate that compounds of the invention inhibit HMGB1-induced production of an inflammatory mediator (TNF-α) in mouse bone marrow-derived macrophages. [Figure 10] We demonstrate that compounds of the invention inhibit HMGB1-induced production of inflammatory mediators (TNF-α, i-NOS) and upregulate the M2 biomarker CXCR4 in mouse macrophages. [Figure 11] The compounds of the present invention are shown to produce the anti-inflammatory cytokine IL-10. [Figure 12] FIG. 1 shows that compounds of the present invention (1 and 2) reduced HMGB1-induced production of VEGF in ARPE-19 cells. [Figure 13] The compounds of the present invention are shown to have broad spectrum antibacterial activity. [Figure 14] It is demonstrated that compounds of the invention inhibited biofilm formation. [Figure 15] The broad spectrum antibacterial activity of the compounds of the present invention is shown to be due to disruption of cell membranes. [Figure 16] The compounds of the present invention demonstrate no binding to plasma proteins, serum proteins. [Figure 17] It is shown that the compounds of the present invention are not toxic to fibroblasts. [Figure 18] 1 shows a synthetic scheme for preparing compound 11. [Figure 19] A synthetic scheme for preparing compounds 22-23 is provided. [Figure 20] A synthetic scheme for preparing compounds 24-25 is provided. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0008] In sepsis caused by Gram-negative bacteria, lipopolysachharide (LPS) activates the immune system through the signaling receptor Toll-like receptor 4 (TLR4) and initiates the process of production of inflammatory cytokines (TNF-α, IL-1β, IL-6, ROS) that cause hyperinflammation. Therefore, some researchers have tried to develop antagonists that inhibit the storm of inflammatory molecules by blocking either the activation through TLR or downstream signaling pathways. However, with the exception of Eritoran, an LPS analogue that failed in clinical trials, probably due to poor clinical trial design, no targeted molecules have progressed beyond experimental and preclinical studies (Opal, SM; Laterre, P.; Francois, B.; et al., Effect of eritoran, an antagonist of md2-tlr4, on mortality in patients with severe sepsis: The access randomized trial. JAMA 2013, 309, 1154-1162). The underlying mechanism of action of most other classes of compounds is not fully understood. (Leon, Carlos G.; Tory, Rita; Jia, Jessica; Sivak, Olena; Wasan, Kishor M. a.Pharmaceutical Research (2008), 25(8), 1751-1761;Savva Athina; Roger Thierry From Frontiers in Immunology (2013), 4387, Language: English, Database: MEDL INE).

[0009] The compounds of the present invention are small molecules that can synergistically inhibit inflammatory microbial infections and upregulate M2 biomarkers such as IL-10 with therapeutic potential to treat sepsis, septicemia and septic shock.

[0010] Posterior ocular neovascular diseases, exemplified by proliferative diabetic retinopathy (PDR), exudative age-related macular degeneration (AMD), and retinopathy of prematurity (ROP), represent a growing and immeasurable health threat and require effective new therapies. Retinal neovascularization associated with PDR is the leading cause of blindness in working-age adults. Choroidal neovascularization (CNV) is responsible for 200,000 new cases of exudative AMD each year in the United States, and this neovascular condition is the leading cause of legal blindness in non-third world countries. The estimated number of AMD patients in 2020 is 196 million, and is expected to increase to 288 million by 2040 (Wong, WL; Su, X.; Li, X.; Cheung, CMG; Klein, R.; Cheng, C.-Y.; Wong, TY, Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health 2014, 2, e106-e116). Pathological angiogenesis associated with ROP is the leading cause of blindness in children under the age of 7 (Harrell, SN; Brandon, DH, Retinopathy of Prematurity: The Disease Process, Classifications, Screening, Treatment, and Outcomes. Neonatal Network 2007, 26, 371-378).

[0011] Several lines of evidence suggest that Toll-like receptor (TLR4) signaling may be associated with pathological changes in retinal diseases, including AMD eyes due to oxidized lipids, lipofuscin, and due to drusen components (Cho, Y.; Wang, JJ; Chew, EY; Ferris, FL; Mitchell, P.; Chan, C.-C.; Tuo, J., Toll-like Receptor Polymorphisms and Age-Related Macular Degeneration: Replication in Three Case-Control Samples. Investigative Ophthalmology & Visual Science 2009, 50, 5614-5618). Once activated, TLR4 may contribute to the pathogenesis of AMD through multiple mechanisms, such as the release of TNF-α, interleukin-1β, and other proinflammatory mediators. TLR4 activation can suppress Wnt signaling, reduce growth factor expression, secretion, and increase photoreceptor death in response to oxidative stress, as well as cause oxidative damage to the outer segments of photoreceptors. TLR4 has been shown to directly act on several inflammation-related signaling pathways, including MAPK, NFκ-β, and Jak1 / Stat1, and to mediate neurotoxicity via caspase-3, neuronal iNOS, and ERK1 / 2, JNK1 / 2, and p38. Interestingly, TLR4-mediated microglial cell activation by endogenous photoreceptor proteins in retinal inflammation can exacerbate retinal cell death.Finally, release of high mobility group box 1 in ischemic neural tissue has been shown to initiate TLR4-dependent responses that contribute to retinal angiogenesis (He, C.; Sun, Y.; Ren, X.; Lin, Q.; Hu, X.; Huang, X.; Su, S.-B.; Liu, Y.; Liu, X., Angiogenesis mediated by toll-like receptor 4 in ischemic neural tissue. Arterioscler Thromb Vasc Biol. 2013, 33(2):330-8).

[0012] Therefore, there is a need for more effective treatment for inflammation, especially for both atrophic and wet AMD pathogenesis.Therefore, the compounds and methods described herein demonstrate that inhibiting TLR4 activity has therapeutic value in AMD and other retinal diseases.The compounds of the present invention are small molecules that can synergistically inhibit angiogenesis, inflammation, and promote phagocytosis, and have therapeutic potential for treating AMD.

[0013] However, prior to the present disclosure, no studies have been performed on dry / wet AMD, diabetic retinopathy, or any There appear to be no published reports on the use of chitohexaose (compound 1), chitohepatose (compound 2) and chitooctaose (compound 3) and their derivatives as TLR4 antagonists to inhibit inflammation and angiogenesis in ocular indications such as chronic ocular inflammation.

[0014] In one embodiment, the principles of the present disclosure relate to a compound of formula (I):

[0015] [ka] (In the formula, R=H, C(O)R1, alkyl, benzyl, substituted benzyl, R1=CH3, alkyl, piperidine nitroxyl R2=H, C(O)R1, or An acyloxyalkyl carbamate of the formula: R2 = C(O)OCHR3OC(O)OR4, piperidine nitroxyl R3=H, CH3, C2H5, isopropyl R4 = optionally substituted alkyl group X=O, NH, S R5 = alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl, heteroalkyl, heterocycloalkyl, piperidine nitroxyl, piperidine N-hydroxylamine (n = 0 to 7) The present invention provides a compound of the formula:

[0016] In another embodiment, the present disclosure provides a compound of formula (II)

[0017] [ka] (In the formula, n=2 to 7) The present invention provides a compound of the formula:

[0018] Additional compounds of the present disclosure include the following structures:

[0019] [ka]

[0020] Compounds (2, 3) of the present disclosure showed unexpectedly potent activity in inhibiting LPS- and HMGB1-induced inflammatory biomarkers (TNF-α, IL-1β, and IL-6) in mouse bone marrow-derived macrophages and human monocytes. Compounds 1 and 2 reduced the production of VEGF in ARPE-19 cells. Compound 2 showed a significant reduction in CNV size in a laser-induced mouse model of wet AMD. Compounds (1-3) of the present invention can be synthesized using the synthetic scheme shown in FIG. 19 in conjunction with knowledge available in the prior art and can be modified as necessary.

[0021] In another embodiment, the present invention provides a compound represented by formula (III):

[0022] [ka] (In the formula, n=0~5 R=COR1 R1=CH3, alkyl) The present invention provides a compound of the formula:

[0023] Further compounds of the invention include the following structures shown below:

[0024] [ka]

[0025] Compound (4) of the present invention showed unexpectedly superior activity in inhibiting LPS-induced inflammatory biomarkers (TNF-α, IL-1β, and IL-6) in human monocytes. As shown in Figures 2-4, compound 4, at 10 mg / kg intravenous (IV) dose, demonstrated superior efficacy in protecting mice in a cecal ligation and puncture (CLP) sepsis model against organ dysfunction and death, statistically significantly down-regulating inflammatory cytokines such as TNF-α, IL-1β, and IL-6.

[0026] The compounds of the present invention (4-6) can be synthesized using the reported procedures described in Mohamed R. E et al, Carbohydrate research, 2001, 331, 129-142.

[0027] In another embodiment, the present invention provides a compound represented by formula (IV)

[0028] [ka] 1. (In the formula, R=H and C(O)R1 R1 = piperidine nitroxyl or piperidine N-hydroxylamine (n = 0 to 7) The present invention provides a compound of the formula:

[0029] Further compounds of the invention include the following structures shown below:

[0030] [ka]

[0031] [ka]

[0032] Compound (11) of the present invention showed unexpectedly superior activity in inhibiting LPS-induced inflammatory biomarkers (TNF-α, IL-1β and IL-6) in human monocytes. Thus, the compounds find use as anti-inflammatory compounds. Compounds (7-11) of the present invention can be synthesized using the synthetic scheme shown in Figure 18, in combination with knowledge available in the prior art.

[0033] In another embodiment, the present invention provides a compound of formula (V)

[0034] [ka] (In the formula, n=0~5 R=H, C(O)CH3, C(O)-Piperidine nitroxy, C(O)-Piperidine N-hydroxyl R1 = alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl, piperidinium N-nitroxyl, piperidine N-hydroxyl The present invention provides a compound of the formula:

[0035] Further compounds of the invention include the following structures shown below:

[0036] [ka]

[0037] Compounds (12-25) of the present invention showed inhibition of LPS-induced inflammatory biomarkers (TNF-α, IL-1β, and IL-6) in human monocytes and upregulated the M2 biomarker IL-10, an anti-inflammatory cytokine. Compound 12 also showed broad-spectrum antibacterial activity against gram-negative and gram-positive bacteria and fungi. Compound 12 unexpectedly inhibited biofilm formation by MSSA and MRSA. Compound 25 demonstrated high survival, organ protection in a CLP mouse model of sepsis when administered intravenously (10 mg / kg dose). Thus, the compounds described herein find use as anti-inflammatory molecules in some embodiments. In some embodiments, the compounds are anti-infective or antibacterial.

[0038] [ka] During the ceremony, n=0~1 R=benzyl, substituted benzyl, R1=COCH3, N-dimethylmaleimide, R3 = cyclohexyl, p-nitrophenyl, piperidine nitroxy, piperidine-N- hydroxyl, p-methoxyphenyl.

[0039] Further compounds of the invention include the following structures shown below:

[0040] [ka]

[0041] The compounds of the present invention showed inhibition of LPS-induced inflammatory biomarkers (TNF-α, IL-1β and IL-6) in human monocytes and upregulated IL-10. Compound 15 also showed broad-spectrum antibacterial activity against Gram-negative bacteria, Gram-positive bacteria and fungi. Compound 15 unexpectedly inhibited biofilm formation by MSSA and MRSA. Compound 15 demonstrated high survival, organ protection in the CLP mouse model of sepsis when administered intravenously (5.0 mg / kg dose). The compounds of the present invention can be synthesized using the synthetic scheme shown in Figure 19, which was developed by the present inventors in conjunction with knowledge available in the prior art.

[0042] Further, certain embodiments include pharmaceutically acceptable salts of the compounds according to the invention. Pharmaceutically acceptable salts include, but are not limited to, soluble or dispersible forms of the compounds according to the invention that are suitable for treating diseases without inappropriate undesirable effects such as allergic reactions or toxicity. Representative pharmaceutically acceptable salts include, but are not limited to, acid addition salts such as acetates, citrates, benzoates, lactates or phosphates, and base addition salts such as lithium, sodium, potassium or aluminum.

[0043] formulation In some embodiments, the compounds of the present disclosure are incorporated into parenteral formulations. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular and intraarterial injections using various infusion techniques. Intraarterial and intravenous injections as used herein include administration by catheter. Preferred for certain indications are administration methods that allow rapid access to the tissue or organ to be treated, such as intravenous injections for the treatment of endotoxemia or sepsis.

[0044] The compounds of the present disclosure are administered at doses that adequately inhibit LPS activation of target cells, and generally, these doses are preferably between 50 and 3000 mg / patient, or between 100 and 2500 mg / patient. The dosage is preferably once a day for 28 days, more preferably twice a day for 14 days, or most preferably three times a day for 7 days.

[0045] Pharmaceutical compositions containing the active ingredient may be in any form suitable for the intended method of administration.

[0046] The aqueous suspensions of the present invention contain the active substance in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as naturally occurring phospholipids (e.g., lecithin), condensation products of alkylene oxides with fatty acids (e.g., polyoxyethylene stearates), condensation products of ethylene oxide with long chain aliphatic alcohols (e.g., heptadecaethyleneoxycetanol), condensation products of ethylene oxide with fatty acids and partial esters derived from hexitol anhydrides (e.g., polyoxyethylene sorbitan monooleate). The aqueous suspensions may also contain one or more preservatives, such as ethyl p-hydroxybenzoate or n-propyl p-hydroxybenzoate.

[0047] The pharmaceutical compositions of the present invention are preferably in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to well-known techniques using the above-mentioned suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a 1,3-butanediol solution, or can be prepared as a lyophilized powder. Among the acceptable vehicles and solvents that can be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils can conventionally be used as a solvent or suspending medium. For this purpose, any mild fixed oil can be used, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can also be used in the preparation of injectables.

[0048] In some embodiments, the formulation comprises PLA or PLGA microparticles and may be further mixed with Na2HPO4, hydroxypropyl methylcellulose, polysorbate 80, sodium chloride, and / or disodium edetate.

[0049] Preparations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions that may contain antioxidants, buffers, bacteriostats, and solutes that render the preparation isotonic with the blood of the intended recipient, as well as aqueous and non-aqueous sterile suspensions that may contain suspending agents and thickening agents.The preparations may be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition, requiring only the addition of a sterile liquid carrier, such as water for injection, immediately prior to use.Extemporaneous injection solutions and suspensions may be prepared from sterile powders of the type described above.

[0050] However, it will be understood that the specific dose level for any particular patient will depend on a variety of factors, including the activity of the particular compound used, the age, weight, general health, and sex of the individual being treated, the time and route of administration, excretion rate, other drugs previously administered, and the severity of the particular disease being treated.

[0051] In some embodiments, the compositions of the present disclosure also contain about 80% to about 99.5%, preferably about 90 or 95% to about 98.5%, of a compatible non-aqueous pharma- ceutically acceptable topical vehicle. Some vehicles are described in U.S. Pat. No. 4,622,433, which is incorporated herein by reference for purposes of this disclosure. No. 1,075. Although these vehicles are preferably water-free, the compositions of the present invention may contain up to about 5% water without significantly adversely affecting the formation of the desired gel. These non-aqueous vehicle components are also well known in the pharmaceutical industry and include (but are not limited to) short chain alcohols and ketones and emollients, such as hydrocarbon oils and waxes, lanolin and lanolin derivatives, silicone oils, monoglycerides, diglycerides, and triglyceride esters, fatty alcohols, fatty acid alkyl and alkenyl esters, dicarboxylic acid alkyl and alkenyl diesters, polyhydric alcohols and their ether and ester derivatives, wax esters, and beeswax derivatives. Preferred vehicles incorporate methanol, ethanol, n-propanol, isopropanol, butanol, polypropylene glycol, polyethylene glycol, and mixtures of these components. Particularly preferred vehicles include ethanol, n-propanol, and butanol, especially ethanol. These preferred solvents can also be combined with other ingredients such as diisopropyl sebacate, isopropyl myristate, methyl laurate, silicones, glycerin and mixtures of these ingredients to provide non-aqueous media that are also useful in the present invention. Of these additional ingredients, diisopropyl sebacate is particularly useful. In fact, preferred media include mixtures of ethanol and diisopropyl sebacate in a weight ratio of about 4:1 to about 1:4. Preferred media contain about 15% to about 35% diisopropyl sebacate and about 65% to about 85% ethanol.

[0052] The composition of the present invention may further contain compatible auxiliary components that are commonly used in the formulation of topical pharmaceutical compositions at the use levels established in the art.These auxiliary components may include, but are not limited to, pharmacoactive ingredients (auxiliary antibacterial or anti-inflammatory ingredients, such as steroids), or ingredients used to enhance the formulation itself (such as excipients, dyes, fragrances, skin penetration aids, stabilizers, preservatives, and antioxidants).The composition of the present invention is capable of gel formation without the need for the presence of traditional gelling agents, and thus such agents are preferably not included.Examples of such agents include pharmacopoietin acidic carboxypolymers, such as the Carbopol compounds available from BFGoodrich Chemicals, Cleveland, Ohio.

[0053] The gel compositions of the present invention can be formulated by conventional mixing of the above ingredients. Gel formation occurs within about 2 minutes to about 16 hours after mixing, depending on the ingredients used.

[0054] In one embodiment, creams, lotions or gels packaged in a common trigger spray container adhere firmly to the area of ​​interest after a regular dose of cream is sprayed from the container. This is described in WO 98 / 51273, which is incorporated herein by reference. Thus, in one aspect, the present disclosure provides a pharmaceutical non-aerosol spray composition for topical application comprising a compound described herein, alone or in combination. The compound is present in the cream, lotion or gel in an amount ranging from 0.1% to 20% by weight, or in some embodiments from 1% to 15% by weight, or in some embodiments from 2% to 10% by weight. The compounds used in the present invention can be incorporated into a neutral hydrophilic matrix cream, lotion or gel. In a first preferred embodiment, the cream or lotion matrix for topical application is characterized by a polyoxyethylene alkyl ether. In a second preferred embodiment, the gel is characterized by a high molecular weight polymer of cross-linked acrylic acid. Polyoxyethylene alkyl ethers are non-ionic surfactants that are widely used as emulsifiers for water-in-oil and oil-in-water emulsions, primarily in topical pharmaceutical formulations and cosmetics. This is characterized in the present invention as the base for a triggerable non-aerosol cream or lotion. The cross-linked acrylic acid polymer (carbomer) used to form the gel is another object of the present invention.

[0055] Thus, a particularly suitable base for non-aerosol sprays is a cream or lotion containing 1-25% polyoxyethylene alkyl ether, 3-40% moisturizer and 0.1-1% preservative(s), the remainder to reach 100% being purified water. Suitably, the polyoxyethylene alkyl ether may be one or any combination selected from the group consisting of polyoxyl 20 cetostearyl ether (Atlas G-3713), polyoxyl 2 cetyl ether (ceteth-2), polyoxyl 10 cetyl ether (ceteth-10), polyoxyl 20 cetyl ether (ceteth-20), polyoxyl 4 lauryl cetyl ether (laureth-4), polyoxyl 23 lauryl cetyl ether (laureth-23), polyoxyl 2 oleyl ether (oleth-2), polyoxyl 10 oleyl ether (oleth-10), polyoxyl 20 oleyl ether (oleth-20), polyoxyl 2 stearyl ether (steareth-2), polyoxyl 10 stearyl ether (steareth-10), polyoxyl 20 stearyl ether (steareth-20) and polyoxyl 100 stearyl ether (steareth-100). Suitable moisturizing agents may be one or any combination selected from the group consisting of propylene glycol, polyethylene glycol, sorbitol or glycerin.Suitable preservatives are one or any combination selected from the group consisting of methylparaben, propylparaben, benzyl alcohol, benzoic acid, sodium benzoate, sorbic acid and its salts or phenylethyl alcohol.

[0056] Another suitable base for non-aerosol sprays is a gel containing 0.1-2.0% carbomer, 0.1-1% alkaline solution, 3-40% humectant and 0.1-1% preservative or preservatives, the remainder being purified water to reach 100%. Suitably, the carbomer may be one or any combination selected from the group consisting of carbomer 934, carbomer 940 or carbomer 941. Suitable humectants, preservatives and purified water for gels are the same as for creams or lotions. Other sprayable formulations are described in US Patent Application Publication No. 2005 / 00255048, which is expressly incorporated herein by reference.

[0057] Ophthalmic preparations (topical and intravitreal): The compound of the present invention typically comprises a small percentage of the total ophthalmic composition.The compound of the present invention typically comprises at least 0.01 w / v%, more typically comprises at least 0.1 w / v%, and even more typically comprises at least 0.5 w / v% of the ophthalmic composition.The compound of the present invention also typically comprises no more than 5.0 w / v%, more typically comprises no more than 3.0 w / v%, and even more typically comprises no more than 1.5 w / v% of the ophthalmic composition.

[0058] Ophthalmic compositions also typically include a suitable ophthalmic vehicle for delivering the compound to the eye. Ophthalmic compositions can be configured for topical or intravitreal application to the eye, and it is believed that the ophthalmic vehicle may vary depending on the application method. In general, for either topical or intravitreal application, the ophthalmic composition is aqueous and preferably includes a substantial amount of water. Typically, the composition includes at least 30 w / v%, more typically at least 80 w / v%, and even more typically at least 90 w / v% water (e.g., purified water).

[0059] For intravitreal application, the ophthalmic composition can comprise or consist essentially of water and the compound of the present invention, especially when the ophthalmic composition is applied to the eye with a syringe. For sustained drug release, a PLGA or PLA microparticle formulation of the compound of the present invention is used as described in Shelke et al [Drug Deliv Transl Res. 2011, (1): 76-90]. Of course, the ophthalmic composition can also contain other ingredients such as Na2HPO4, hydroxypropylmethylcellulose, polysorbate 80, sodium chloride, and disodium edetate.

[0060] The vehicle may be solely or essentially water for topical application, particularly if the topical application is performed immediately after the water is combined with the test compound or if the composition is packaged in a manner that prevents contamination. However, when the ophthalmic composition is applied as an ophthalmic composition that is administered multiple times over an extended period of time (e.g., once, twice, three or more times a day over multiple days, as drops from an eye dropper), the ophthalmic composition will likely contain additional components such as antimicrobial agents or preservatives or systems, surfactants, buffers, isotonicity agents, antioxidants, viscosity modifiers, combinations thereof, and the like.

[0061] For topical application, the composition of the present invention typically includes an antibacterial agent. Potential antibacterial agents include, but are not limited to, hydrogen peroxide, chlorine-containing preservatives such as benzalkonium chloride, or others. However, according to a preferred embodiment, the composition of the present invention is completely or substantially free of non-polymeric quaternary antibacterial agents such as benzalkonium chloride (BAK). The most preferred antibacterial agents in the pharmaceutical composition include polymeric quaternary ammonium compounds.

[0062] As used herein, the phrase "substantially free" when referring to a component of an ophthalmic composition means that the ophthalmic composition may be completely devoid of that particular component or may contain only trace amounts of that particular component.

[0063] The polymeric quaternary ammonium compounds useful in the compositions of the present invention are those that have antibacterial effects and are ophthalmically acceptable. Preferred compounds of this type are described in U.S. Patent Nos. 3,931,319; 4,027,020; 4,407,791; 4,525,346; 4,836,986; 5,037,647 and 5,300,287; and PCT Publication WO 91 / 09523 (Dziabo et al.), which are expressly incorporated herein by reference. The most preferred polymeric ammonium compounds are polyquaternium 1, or compounds known as POLYQUAD™ or ONAMERM™, having a number average molecular weight of 2,000 to 30,000. Preferably, the number average molecular weight is 3,000 to 14,000.

[0064] Polymeric quaternary ammonium compounds are generally used in the suspensions of the invention in amounts greater than about 0.00001% w / v, more typically greater than about 0.0003% w / v, and even more typically greater than about 0.0007% w / v of the suspension. Moreover, polymeric quaternary ammonium compounds are generally used in the compositions of the invention in amounts less than about 3% w / v, more typically less than about 0.003% w / v, and even more typically less than about 0.0015% w / v of the composition.

[0065] The antimicrobial agent of the composition of the present invention may additionally or alternatively include an antimicrobial system such as a borate / polyol complex system. The term "borate" as used herein means boric acid, borate salts, boric acid derivatives and other pharma- ceutically acceptable borates, or combinations thereof. Most suitable are boric acid, sodium borate, potassium borate, calcium borate, magnesium borate, manganese borate, and other borate salts. Borates interact with polyols such as glycerol, propylene glycol, sorbitol, and mannitol to form borate polyol complexes. The type and ratio of such complexes depends on the number of OH groups of the polyol on adjacent carbon atoms that are not in a trans configuration relative to each other. It is understood that the weight / volume percentages of polyol and borate components include their amounts whether or not they are part of a complex.

[0066] As used herein, the term "polyol" refers to a polyol having at least one hydroxyl group on each of two adjacent carbon atoms that are not in a trans configuration relative to each other. The term polyol includes any compound having the formula: Polyol can be linear or cyclic, substituted or unsubstituted, or mixtures thereof, so long as the resulting complex is water soluble and pharma- ceutically acceptable. Examples of such compounds include sugars, sugar alcohols, sugar acids, and uronic acids. Preferred polyols are sugars, sugar alcohols, and sugar acids, including, but not limited to, mannitol, glycerin, xylitol, sorbitol, and propylene glycol.

[0067] When used, the borate / polyol complex antimicrobial system (i.e., borate and polyol together) typically constitutes at least 0.05 w / v%, more typically at least 0.5 w / v%, and sometimes at least 1 or at least 1.2 w / v% of the composition, and typically constitutes less than 5 w / v%, more typically less than 2.2 w / v%, and sometimes less than 1.6 w / v% of the composition. The ratio of borate to polyol (weight to weight) in the composition is typically 1:1 to 1:10, more typically 1:2 to 1:4 (e.g., about 1:3).

[0068] Tyloxapol, polysorbate-80 and polyoxyl hydrogenated castor oil are preferred surfactants. Tyloxapol is a highly preferred surfactant. When used, the surfactant is typically present at a concentration of at least 0.01 w / v% of the composition, more typically at least 0.025 w / v%, in some cases at least 0.1 w / v%, and typically at a concentration of less than 5 w / v% of the composition, more typically less than 2.0 w / v%, in some cases less than 1.0 w / v%.

[0069] Compositions of the invention for use in topical application are typically formulated to be compatible with the eye. Ophthalmic compositions intended for direct application to the eye are formulated to have a pH and isotonicity that is compatible with the eye. The compositions typically have a pH in the range of 4 to 9, preferably 5.5 to 8.5, and most preferably 5.5 to 8.0. Particularly desirable pH ranges are 6.0 to 7.8, and more particularly 6.4 to 7.6. The compositions have an osmolality of 200 to 400 or 450 milliosmoles per kilogram (mOsm / kg), more preferably 240 to 360 mOsm / kg.

[0070] A preferred composition of the invention is a multi-dose ophthalmic composition, for example, the composition is in an eye drop formulation and can be administered topically to the eye as one or more drops once, twice, three or more times daily, in which case the composition preferably has sufficient antimicrobial activity to meet the preservative effectiveness requirements of the USP (United States Pharmacopeia) as well as other preservative effectiveness standards for aqueous pharmaceutical compositions.

[0071] Preservative potency standards for multi-dose ophthalmic solutions in the United States and other countries / regions are set forth in the following table:

[0072] [Table 1]

[0073] The European Pharmacopoeia has two preservative effectiveness standards, "A" and "B".

[0074] The criteria described above for USP27 are substantially identical to the requirements described in previous editions of the USP, particularly USP24, USP25, and USP26.

[0075] As an added advantage, these ophthalmic compositions containing the TLR4 antagonist compounds of the present invention are suitable for topical application to the eye.

[0076] The formulations described herein may also contain additional active ingredients such as, but not limited to, antibacterial agents, analgesics, etc., as described above.

[0077] As such, the compounds and formulations described herein find use in treating a variety of ocular inflammatory diseases, including, but not limited to, AMD, sepsis and severe sepsis, SIRS and septic shock. The method includes administering an effective amount of the antimicrobial and anti-inflammatory compositions described herein to a patient in need thereof to treat the disease or disorder. Medical uses of such compounds include sepsis, neonatal sepsis, toxemia, septic shock, burns and wounds, infective endocarditis, biofilm inhibition, ocular infections, ocular inflammation, ocular vascular For the treatment and / or management of neoplasia, diabetic retinopathy, retinopathy of prematurity, uveitis, rheumatoid arthritis (RA), atherosclerosis, inflammatory bowel disease (IBD), asthma, chronic obstructive pulmonary disease, bronchopulmonary dysplasia, fever syndromes, cachexia, psoriasis, autoimmune diseases, heart disease, retinoblastoma, cancer, and / or any disorder associated with inflammation, immunomodulation and microbial infection. [Example]

[0078] The following examples, including the experiments performed and results achieved, are provided for illustrative purposes only and should not be construed as limiting the invention. EXAMPLES

[0079] A series of compounds of the present invention effectively bind to the TLR4 receptor and do not bind to the TLR2 receptor: ELISA plates were coated with human monocyte lysate (isolated from commercial LeukoPak blood samples) followed by a series of compounds (10 μM) as shown in Figure 6. This was then incubated with human monocyte lysate and then probed with anti-TLR4 and anti-TLR2 antibodies. The plate was developed with an anti-human IgG-HRP positive control. Compounds 1-3 bind effectively to the TLR4 receptor and not to the TLR2 receptor. Larger chain length analogs showed stronger antagonism (Figure 7A). Similarly, other analogs were evaluated for the TLR4 antagonist assay as shown in Figure 7B. Briefly, 500,000 cells were grown in RPMI with 10% FBS O / N in two 24-well plates. The next day, the medium was removed without disturbing the bottom layer and different concentrations of compounds were added to a total volume of 0.5 ml RPMI and incubated for 48 hours. Cells were harvested and the harvested culture medium was analyzed using a human TLR4 ELISA kit according to the manufacturer's instructions (Raybiotech). EXAMPLES

[0080] Compounds were tested for inhibiting the production of inflammatory mediators in human monocytes: To understand the structural requirements and limitations for probing the TLR4 binding pocket for optimal potency and efficacy, we tested the ability of chitooligomers to inhibit LPS-induced inflammation in human monocytes (Figure 8A-B). Compounds 1-4 statistically significantly inhibited LPS-induced cytokines TNF-α, IL-1β, and IL-6 at 10 μM concentrations. Compounds 2 and 4 (10 μM) were found to be more potent than chitohexaose (compound 1) (10 μM) in terms of percent inhibition of LPS-mediated induction of inflammatory cytokines (p<0.001 for LPS vs. Chtx, while p<0.0001 for LPS vs. compounds 2 or 4). The protocol was performed as described in (Panda, SK; Kumar, S.; Tupperwar, NC; Vaidya, T.; George, A.; Rath, S.; Bal, V.; Ravindran, B., Chitohexaose Activates Macrophages by Alternate Pathway through TLR4 and Blocks Endotoxemia. PLoS Pathog 2012, 8, e1002717). Human monocytes were stimulated with LPS for 48 h along with a series of compounds (10 μM). TNF-α, IL-1β, and IL-6 were quantified in the culture supernatants according to the manufacturer's instructions. Similarly, other analogs were evaluated for their ability to inhibit LPS-induced TNF-α production in human monocytes. Compounds 12, 15, 16, 39, 40, 41, 42, and 25 were found to be potent inhibitors of TNF-α at 100 μM concentration (Figure 8B). EXAMPLES

[0081] Compounds 1, 2 and 26 inhibit LPS-induced production of inflammatory mediators (TNF-α) in mouse bone marrow-derived macrophages: Bone marrow-derived mouse macrophages were treated with 100 μM of the above test compounds for 8 hours. Proinflammatory cytokine protein levels, such as TNF-α, were analyzed by real-time RT-PCR. LPS treatment (10 ng / ml) was used as a positive control (Figure 9). EXAMPLES

[0082] Compound 26 inhibits HMGB1-induced production of inflammatory mediators (TNF-α, i-NOS) and upregulates the M2 biomarker CXCR4 in mouse macrophages: The expression of TNF-α and iNOS were both inhibited by compound 26 in macrophages. Interestingly, CXCR4, an M2 macrophage marker, was upregulated by compound 26, suggesting a potential effect on macrophage polarization, suggesting immunomodulatory activity. Mouse bone marrow-derived macrophages were treated with HMGB1 for 8 hours with or without 100 μM compound 26. The mRNA levels of TNF-α, iNOS and CXCR4 were measured by real-time RT-PCR and normalized to the expression levels of control cells ( FIG. 10 ). EXAMPLES

[0083] The compounds of the present invention produce the anti-inflammatory cytokine IL-10: Interleukin 10 (IL-10) is a cytokine with potent anti-inflammatory properties that plays a central role in limiting the host immune response against pathogens, thereby preventing damage to the host and maintaining normal tissue homeostasis. Dysregulation of IL-10 is associated with enhanced immunopathology in response to infection and increased risk of development of many autoimmune diseases. Here, compounds of the present invention were evaluated for upregulating IL-10 levels in PBMCs using an ELISA assay (Figure 11). Briefly, 500,000 cells were grown in RPMI with 10% FBS O / N in two 24-well plates. The next day, the medium was removed without disturbing the bottom layer and different concentrations of compounds (0, 1, 10, 100 μM) were added to a total volume of 0.5 ml in RPMI, which was incubated for 48 hours. Cells were harvested and the harvested culture fluid was analyzed using an ELISA kit according to the manufacturer's instructions (Raybiotech). EXAMPLES

[0084] Chitohexaose (compound 1) protected mice from lethal Gram-negative sepsis caused by E. coli: In an in vivo mouse model, chitohexaose (compound 1) protected mice from lethal Gram-negative sepsis caused by E. coli. A previously reported bacterial sepsis model [Roger et al, Proc Natl Acad Sci US A. 2009 Feb 17;106(7):2348-52] was employed to test the efficacy of compound 1 (Figure 1). 2x105 CFU of E. coli (ATCC-25922) was injected intraperitoneally into BALB / c mice with or without compound 1 (250μg / animal). E. coli-mediated sepsis induced death, but mice co-treated with compound 1 were protected from sepsis-induced death (40%). The above results illustrated that bacteria-induced sepsis and death were inhibited and delayed for a period of time that could be a therapeutic time window. EXAMPLES

[0085] Compounds 4, 15 and 25 protected mice from CLP-induced polymicrobial infection and sepsis: To prove the concept and demonstrate the feasibility, we tested compound 4 in a CLP mouse model. The CLP model consists of perforation of the cecum, which releases fecal material into the peritoneal cavity and induces an exacerbated immune response through polymicrobial infection. This model meets the clinically relevant human condition. A previously reported CLP sepsis protocol (Toscano et al, Journal of VIsualized Experiments: 2011, (51), 2860) was adopted to test the efficacy of compound 4. C57BL / 6 mice (Jackson Lab) in CLP and CLP plus saline (0.5%) and antibiotic (primaxin, 5 mg / kg) groups were cultured at 100°C for 12 h. Ratories, 10-12 weeks, N = 15) were intravenously injected with compound 4 (10 mg / kg) 16 and 40 hours after surgery. As a result, CLP-mediated sepsis induced organ dysfunction and death, but co-treatment of mice with compound 4 protected mice (about 93%) from sepsis-induced death (14 / 15), as shown in Figure 2. We also demonstrated that in combination with the standard point of care antibiotic primaxin (5 mg / kg), compound 4 protected mice (about 93%) from sepsis-induced death (14 / 15) while delaying clinical symptoms such as hypothermia, shivering, huddling, anorexia, decreased movement, and increased heart and respiratory rates.

[0086] Compound 25 (10 mg / kg) and compound 15 (5.0 mg / kg) also protected mice (about 60%) from sepsis-induced death, as shown in Figure 5. We also demonstrated that in combination with the standard point-of-care antibiotic primaxin (5 mg / kg), both compounds protected mice (about 60%) from sepsis-induced death while delaying clinical symptoms such as hypothermia, shivering, huddling behavior, anorexia, decreased movement, and increased heart and respiratory rates. EXAMPLES

[0087] Histopathology of organ tissues in mice after CLP Hematoxylin and eosin (H / E) staining of various organs of sham, CLP and compound 4 treated mice was performed. In summary, after the tissues were harvested, they were fixed in 10% neutral buffered formalin, processed, embedded in paraffin and sectioned at 4μ for routine hematoxylin and eosin staining. CLP mice showed microthrombi and congestion in the heart, lung, liver, kidney and brain, increased germinal center size in the spleen, villous necrosis in the intestine and loss of testicular epithelium. Treatment with compound 4 reversed all these changes to a large extent and the tissues resembled the sham group (Figure 3). EXAMPLES

[0088] Post-CLP serum biomarker testing: Plasma collected from the tail vein 48 hours after surgery was stored at -30°C and analyzed for TNF-α, IL-6, and IL-β levels in sham, CLP, CLP+compound 4, CLP+primaxin, CLP+primaxin+compound 4, and control (saline-injected) groups. Compound 4, alone or in combination with the antibiotic primaxin, statistically significantly reduced the levels of TNF-α, IL-1β, and IL-6 compared to the CLP mice group (n=4, p<0.0005) (Figure 4). In summary, the above cytokines were estimated by sandwich ELISA using commercially available ELISA kits. The ELISA plate was coated with capture antibody and subsequently incubated with the test samples and appropriate standards. It was then probed with biotin-labeled secondary antibody and avidin-peroxidase. Color was developed using TMB and the optical density (OD) was recorded. EXAMPLES

[0089] The compounds of the present invention have broad spectrum antibacterial activity: The compounds were screened against selected Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae), Gram-positive bacteria (MRSA) and fungi (Candida albicans) mainly found in burn and septic wounds. Most of them showed antibacterial activity with MIC90 of 50-200 mg / L (Figure 13). All prepared compounds were evaluated in Minimum Inhibitory Concentrations (MIC) assays with both test and control substances according to the Clinical Laboratory Standards Institute (CLSI) guidelines for broth microdilution susceptibility testing. In brief, test and control compounds were dissolved in DMSO, diluted to appropriate concentrations and added to a 96-well microdilution tray. Staphylococcus aureus, E. coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii and Candida albicans were assayed against 100% glycerol (GlcNAc) and 100% glycerol (GlcNAc) in 100% glycerol (GlcNAc) samples. Brain Heart Infusion Broth (BHI) was used for testing with bacterial strains such as D. albicans. Compounds were serially diluted from 200 μg / ml to 0.0625 μg / ml and plated in 96-well plates seeded with approximately 1x105 CFU of each organism. The MIC endpoint was determined for each compound after 24 hours as the lowest concentration of test or control compound that completely inhibited the growth of the organism in microdilution. EXAMPLES

[0090] Compounds of the invention inhibited biofilm formation: Based on the in vitro antibacterial MIC data, we selected three compounds 1, 12 and 15 for further testing against MRSA. All three compounds showed better activity against MRSA and MSSA strains compared to colistin (a standard of care antibiotic) used as a positive control (Figure 14). Furthermore, biofilm inhibition and eradication activities against biofilm cells were tested as previously described (Ceri, H.; Olson, ME; Stremick, C.; Read, RR; Morck, D.; Buret, A., The CalgaryBiofilm Device: New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms. Journal of Clinical Microbiology 1999, 37, 1771-1776). The minimum biofilm eradication concentrations (MBIC) of compound 15 against MRSA was superior to colistin. Thus, these compounds with activity against S. aureus biofilms have a significant impact on the control of difficult-to-eradicate biofilm-mediated intravascular infections [Li et al, J Infect Dis. 2016 Nov 1;214(9):1421-1429;Archer, NK; Mazaitis, MJ; Costerton, JW; Leid, JG; Powers, ME; Shirtliff, ME, Staphylococcus aureus biofilms: Properties, regulation and roles in human disease. Virulence 2011, 2, 445-459]. In summary, we used the Calgary Biofilm Device (CBD) technology for biofilm susceptibility to compounds.CBD generates 96 equivalents of biofilm for antibiotic susceptibility assays using standard 96-well techniques. Susceptibility to a standard panel of compounds and antibiotics was determined by the National Committee for Clinical Laboratory Standards (NCCLS) as previously described. EXAMPLES

[0091] The broad spectrum antibacterial activity of the compounds of the present invention is due to the disruption of cell membranes: The effect of AVR compounds on exponentially growing MRSA and membrane integrity was evaluated. MRSA resuspended in phosphate buffered saline was exposed to MICs of antibiotics and AVR compounds 1, 12, and 15 in brain heart infusion broth for 30 min and 1 h, and the absorbance of leaking cellular material in the culture filtrate was measured as detected by optical density at 260 nm (Figure 15). EXAMPLES

[0092] The compounds of the present invention do not bind to plasma or serum proteins. One of the major difficulties in designing drug candidates for systemic, oral or topical use is their poor plasma / tissue bioavailability due to binding of drugs to plasma and serum proteins. Therefore, we tested the effect of serum on compound activity by microdilution MIC in DMEM containing 10% bovine serum (GIBCO, MA) (Hurdle, JG; Lee, RB; Budha, NR; Carson, EI; Qi, J.; Scherman, MS; Cho, SH; McNeil, MR; Lenaerts, AJ; Franzblau, SG; Meibohm, B.; Lee, RE, A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. Journal of Antimicrobial Chemotherapy 2008, 62, 1037-1045). The results showed that all compounds were active against MRSA, did not bind to serum proteins and were abundant in the target tissues. This suggested good bioavailability (Figure 16). EXAMPLES

[0093] The compounds of the present invention are not toxic to fibroblasts: Cytotoxicity and therapeutic index were also assessed by exposing the MEF mouse fibroblast cell line (ATCC, Manassas, VA) to the antibiotic colistin and the AVR compounds for 24 hours, followed by the MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, Thermo Fischer, MA] assay as previously described. The cytotoxicity of all AVR compounds in the MEF mouse fibroblast cell line is shown in Figure 17, indicating that the AVR compounds selectively inhibit the growth of MRSA without impairing the proliferation of fibroblast cells, which is critical in the wound healing process. EXAMPLES

[0094] Compounds 1 and 2 reduced the production of VEGF in ARPE-19 cells: The RPE, central to photoreceptor survival and function, is the primary source of the angiogenic factor VEGF and therefore plays a central role in the regulation and growth of choroidal neovascularization leading to AMD (Spilsbury, K.; Garrett, KL; Shen, W.-Y.; Constable, IJ; Rakoczy, PE, Overexpression of Vascular Endothelial Growth Factor (VEGF) in the Retinal Pigment Epithelium Leads to the Development of Choroidal Neovascularization. The American Journal of Pathology 2000, 157, 135-144;Betts, BS; Parvathaneni, K.; Yendluri, BB; Grigsby, J.; Tsin, ATC, Ginsenoside-Rb1 Induces ARPE-19 Proliferation and Reduces VEGF Release. ISRN Ophthalmology 2011, 2011, 184295). As part of our preliminary results to evaluate whether compounds 1 and 2 can inhibit HMGB1 (the endogenous ligand of TLR4), VEGF production in ARPE-19 cells was induced. Figure 12 shows that compounds 1 and 2 (50 μg / mL) effectively reduce HMGB1-induced VEGF production in ARPE-19 cells with statistical significance (p<0.01). 2×105 ARPE-19 cells were seeded in complete medium with 10% serum in 24-well plates for 24 hours and then maintained in serum-free medium for another 24 hours. Cells were treated with 0 μg / mL (medium) or 100 ng / mL HMGB1 with or without 50 μg / mL of test compound for 24 hours. Supernatants were collected and assayed using a human VEGF ELISA kit from Peprotech according to the manufacturer's instructions. RPE cells are located adjacent to the choriocapillaris and other major vasculature of the eye.Thus, these findings suggest that compounds 1 and 2 may have significant effects on inhibiting choroidal and retinal capillary neovascularization (through inhibition of TLR4 and reduction of VEGF), which contributes to the development of AMD and retinopathy. EXAMPLES

[0095] Compound 2 reduced choroidal neovascularization by approximately 60% compared to positive controls in a laser-induced CNV mouse model of wet AMD: To demonstrate the in vivo angiogenesis suppression effects of AVR compounds, we tested the compounds in a laser-induced CNV mouse model (Figure 5). Laser CNV was induced in C57BL / 6 mice (10-12 weeks) using an Iridex Oculight GL 532 nm diode laser (Mountain View, CA) connected to a MicronIV fundus imaging system with a laser injector (Phoenix Research Laboratories, Pleasanton, CA). The parameters used to reproducibly obtain successful laser spots (confirmed by the formation of gas bubbles indicating rupture of Bruch's membrane) were 350 mW, 75 msec, and a spot size of 50 μm. Four laser spots were applied; 2-3 papillary diameters from the optic nerve. Mice were treated with either PBS (negative control), compounds 1, 2, and 26, or a positive control (anti-VEGF antibody) on days 2, 4, and 6 after laser irradiation (n=4-6 mice / group). Compounds 1, 2, and 26 and BSS (vehicle) were administered by intraperitoneal injection once daily. Injection was started 1 day before laser irradiation and continued for 10 days after laser irradiation. By the end of the experiment, the mouse eyes were examined by fluorescein fundus angiography and / or optical coherence tomography (OCT) to visualize the CNV lesions. The animals were then sacrificed and RPE / choroid / sclera flat mounts were prepared and stained with both FITC-conjugated isolectin B4 and anti-ICAM-2 antibodies to quantitatively measure the size of CNV. Two experiments were performed to test the effect of 1, 2, and 26 on laser-induced CNV. As shown in Figure 5, daily intraperitoneal injection of 200 μg of compound 2 was able to reduce the average size of CNV lesions to approximately 60% of the average size of CNV lesions in control mice treated with vehicle only (balanced salt buffer), which was comparable to the positive control. EXAMPLES

[0096] Synthesis of compound 11: To chitotriose (10 mg, 0.015 mmol) in 5 mL of methanol was added a methanol solution of 4-carboxy-TEMPO (4.5 mg, 0.026 mmol). To this was added DCC (4.66 mg, 0.026 mmol) and a methanol solution of cat DMAP, stirred at room temperature for 48 hours, and cooled at 2° C. for 12 hours. Ether was added to precipitate a white solid, which was filtered and dried to give 4.0 mg of a white powder. LC / MS=684(M+1), 1H NMR(DMSO-D6,500MHz):δ 1.15(s,12H), 1.35~1.55(m,4H), 1.97~2.05(bs,10H), 2.43(m,1H), 2.80~3.23(m,4H), 3.25~3. 66(m,11H), 4.07(s,2H), 4.41(s,2H), 4.65(s,2H), 5.18(d,1H), 5.52(bs,2H), 8.15(d,1H,NH).

[0097] Synthesis of compound 30: To a stirred suspension of D-glucosamine 29 (100 g, 0.55 mol) in EtOH (500 mL) was added NaOEt (30 g, 0.55 mol). After 10 min, the mixture was treated with dimethylmaleic anhydride (0.5 equiv.) and stirred for 20 min. Triethylamine (65.2 mL, 0.465 mol) was added and the reaction mixture was again treated with the remaining dimethylmaleic anhydride (0.5 equiv.). The reaction mixture was warmed to 60° C. with stirring for 2 h, the EtOH was evaporated and dried. The residue was treated with pyridine, acetic anhydride and stirred at room temperature for 20 h. The reaction was monitored by TLC, the solvent was evaporated and the residue was poured onto ice, extracted with chloroform (3×1 L), washed with 1 L aqueous hydrochloric acid (3%), saturated sodium bicarbonate solution (1 L), distilled water (1 L) and dried over anhydrous sodium sulfate. The residue was purified by silica gel chromatography using EtOAc (20-30%) in petroleum ether as eluent to give compound 30 (80 g, ca. 37%). 1H NMR (400 MHz, CDCl3): δ 1.91 (3H, s), 1.94 (6H, s), 2.01 (s, 3H), 2.03 (s, 3H), 2.09 (s, 3H), 3.92-3.96 (m, 1H), 4.0-4.12 (dd, 1H), 4.18-4.23 (dd, 1H), 4.30-4.33 (dd, 1H, J = 4.4 Hz), 5.14 (t, 1H, J = 9.2 Hz), 5.69 (t, 1H, J = 9.2 Hz), 6.34 (d, 1H, J = 8.8 Hz).

[0098] Synthesis of compound 31: To a solution of 30 (100 g, 0.219 mol) in DMF at 23°C, hydrazine hydrate (12 ml, 0.219 mol) was slowly added and stirred at the same temperature for 5-6 h and monitored by TLC. The reaction mixture was diluted with ethyl acetate (2 L), washed with water (3×1 L), brine (1 L), dried over Na2SO4, and evaporated to give compound 31 (65 g, ca. 71%). 1H NMR (400MHz, CDCl3):δ 1.85(s,3H), 1.90(s,6H), 1.98(s,3H), 2.05(s,3H), 3.79~3.84(m,1H), 3.95~4. 06(dd,1H), 4.10~4.13(dd,1H), 4.20~4.24(dd,1H), 5.06(t,1H,J=9.6Hz), 5.42 (d,1H,J=8.4Hz), 5.60(t,1H,J=9.6Hz).

[0099] Synthesis of compound 32: To a stirred solution of compound 31 (35 g, 0.084 mol) and imidazole (14.4 g, 0.211 mol) in DCM at 23 °C, TBDMSCl (15.2 g, 0.101 mol) was added portionwise, stirred at the same temperature for 16 h, monitored by TLC, diluted with DCM (1 L), washed with water (2 × 1 L), brine (500 mL), dried over Na2SO4, and concentrated to give the crude product. The residue was purified by silica gel chromatography using EtOAc (15-20%) in petroleum ether as eluent to give compound 32 (27 g, ca. 61%). 1H NMR (400MHz, CDCl3):δ 0.01(s,3H), 0.05(s,3H), 0.76(s,9H), 1.91(s,3H), 1.93(s,6H), 2.01(s,3H), 2.07(s,3H), 3.80~3.83(m,1H), 3.98~4. 03(dd,1H), 4.10~4.14(dd,1H), 4.20~4.24(dd,1H), 5.05(t,1H,J=9.6Hz), 5.36(d,1H,J=8.4Hz), 5.66(t,1H,J=9.6Hz).

[0100] Synthesis of compound 33: To a stirred solution of compound 32 (27 g, 0.051 mol) in MeOH (100 mL) was added NaOMe (2.76 g, 0.052 mol) portionwise at 23 °C and stirred at the same temperature for 3-4 h. The reaction was monitored by TLC, MeOH was concentrated under reduced pressure, diluted with 50 mL of water, pH was adjusted to 6.5-7.0, and the solid was filtered and dried to give pure compound 33 (16 g, ca. 77%). 1H NMR (400MHz, CDCl3):δ 0.03(s,3H), 0.05(s,3H), 0.76(s,9H), 1.94(s,6H), 3.45~3.47(m,1H), 3.57~ 3.61(m,1H), 3.77~3.90(m,3H), 4.21(t,1H,J=8.0Hz), 5.23(d,1H,J=8.0Hz).

[0101] Synthesis of compound 34: A suspension of compound 33 (30 g, 0.074 mol) and dibutyltin oxide (37.25 g, 0.149 mol) in toluene (400 mL) was heated under reflux for 12 h, tetrabutylammonium iodide (55.2 g, 0.149 mol) and benzyl bromide (25.5 g, 0.149 mol) were added, the mixture was gently refluxed for 3 h, the reaction mixture was cooled and concentrated to give the crude product. The residue was purified by silica gel chromatography using 15-20% EtOAc in petroleum ether to give compound 34 (25 g, ca. 60%). 1H NMR (400MHz, CDCl3):δ 0.06(s,3H), 0.02(s,3H), 0.73(s,9H), 1.83~1.93(bs,6H), 3.56~3.61(m,1H), 3.72~3.80(m,2H), 3.86~3.89(dd,1H), 4.09~4.14( dd,1H), 4.53(d,1H,J=12Hz), 4.56~4.63(dd,2H), 4.69~4.76(dd,2H), 5.16(t,1H,J=8.0Hz), 7.15~7.24(m,5H), 7.33~7.37(m,5H).

[0102] Synthesis of compound 35: To a mixture of compound 31 (5 g, 0.012 mol) and CCl3CN (2.06 g, 0.014 mol) in dry CHCl2, DBU (0.37 g, 0.002 mol) was added and stirred at room temperature for 15-16 h. The reaction mixture was concentrated to give the crude product. The crude product was purified by silica gel chromatography using EtOAc (25-35%) in petroleum ether to give compound 35 (3.8 g, 55%). 1H NMR (400 MHz, CDCl3): δ 1.91 (s, 3H), 1.93 (s, 6H), 2.01 (s, 3H), 2.07 (s, 3H), 3.93-4.01 (m, 1H), 3.98-4.03 ( dd,1H), 4.33~4.40(m,2H), 5.20(t,1H,J=9.2Hz), 5.73(t,1H,J=9.2Hz), 6.45(d,1H,J=9.2Hz), 8.67(s,1H).

[0103] Synthesis of compound 36: A mixture of compound 35 (4 g, 0.007 mol) and compound 34 (3.3 g, 0.0057 mol) was placed in an oven-dried round-bottom flask containing activated molecular sieve powder (4Ao). The RB was then filled with argon twice, dry DCM (10 mL) was added, and stirred at 23 °C for 2 h. The resulting reaction mixture was then cooled to -10 °C, and a 0.1 M solution of TfOH in DCM was added, and stirred for an additional 16 h. The reaction mixture was concentrated under reduced pressure to give a crude mixture, which was purified by silica gel chromatography using EtOAc in petroleum ether (25-35%) to give compound 36 (2 g, 30%). 1H NMR (400 MHz, CDCl3): δ -0.005(s,3H), -0.11(s,3H), 0.71(s,9H), 1.76(bs,6H), 1.90(s,3H), 1.95(bs,6H), 1.98(s,3H) ), 3.36~3.44(m,3H), 3.48~3.55(m,3H), 3.80~3.83(m,2H), 3.90~3.93(dd,1H), 4.04~4.12(m,3H ), 4.14~4.20(dd,1H), 4.42(d,1H,J=12.4Hz), 4.57~4.64(dd,2H), 4.81(d,1H,J=12.4Hz), 5.03~ 5.08(m,2H), 5.36(d,1H,J=8.4Hz), 5.61(t,1H,J=9.2Hz), 7.13~7.19(m,5H), 7.33~7.39(m,5H).

[0104] Synthesis of compound 37: AcOH (0.36 mL, 0.0063 mol) was added to a solution of compound 36 (5.5 g, 0.0056 mol) in dry THF (50 mL) and cooled to -5°C. Then, a solution of 1M TBAF (6.3 mL, 0.0063 mol) in THF at -5°C was added and stirred at room temperature for 16 h. After completion of the reaction, the reaction mixture was quenched with saturated NaCl solution, extracted with DCM and concentrated under reduced pressure to give crude compound 37 (3 g, crude), which was used in further reactions without purification. 1H NMR (400 MHz, CDCl3): δ 1.76(s,6H), 1.89(s,3H), 1.95(bs,6H), 1.98(s,3H), 3.38~3.55(m,3H), 3.62~3.66(m ,1H), 3.76~3.80(m,1H), 3.90~3.94(m,1H), 4.06~4.22(m,6H), 4.14~4.20(dd,1H), 4.4 0(d,1H,J=12.8Hz), 4.57~4.64(dd,2H), 4.85(d,1H,J=12.8Hz), 5.01~5.07(m,2H), 5. 33(d,1H,J=8.4Hz), 5.55~5.63(t,1H,J=9.2Hz), 7.11~7.20(m,5H), 7.29~7.42(m,5H).

[0105] Synthesis of compound 38: To a mixture of compound 37 (4 g, 0.0045 mol) and CCl3CN (0.54 mL, 0.0054 mol) in dry CH2Cl2, DBU (0.13 mL, 0.0009 mol) was added and stirred at room temperature for 15-16 h. The reaction mixture was concentrated to give the crude product. The crude product was purified by silica gel chromatography using EtOAc in petroleum ether (25-35%) to give compound 38 (1 g, 20%).

[0106] Synthesis of compounds 39-42: A mixture of compound 38 (1 g, 0.89 mmol) and R-OH (0.7 equiv.) was placed in an oven-dried round-bottom flask containing activated molecular sieve powder (4Ao), then the RB was filled with argon twice, dry DCM (20 mL) was added, and stirred at room temperature for 2 h. The resulting reaction mixture was then cooled to -10 °C, and a 0.1 M solution of TfOH (1.3 mL, 0.13 mmol) in DCM was added, and stirred for an additional 16 h. The reaction mixture was concentrated under reduced pressure to give crude 38 (1 g, 0.89 mmol). A mixture was obtained, and the crude product was purified by silica gel chromatography using EtOAc in petroleum ether (25-35%) to give compounds 39-42 (about 40-45%).

[0107] Compound 39:1H NMR (400MHz, CDCl3):δ 1.76(s,6H), 1.89(s,3H), 1.95(bs,6H), 1.98(s,3H), 3.49~3.51(m,2H), 3.64~3.71 (m,2H), 3.94~3.96(m,1H), 4.15~4.19(m,6H), 4.40(m,1H), 4.56~4.65(m,2H), 4.86 ~4.91(m,1H), 5.06~5.09(m,1H), 5.33(d,1H,J=8.4Hz), 5.55~5.63(t,1H,J=9.2Hz) , 6.91(d,2H,J=8.4Hz), 7.12~7.21(m,5H), 7.29~7.42(m,5H), 8.06(d,2H,J=8.4Hz). LC / MS:M+=982.

[0108] Compound 40: 1H NMR (400 MHz, CDCl3): δ 1.21~1.48 (m, 10H), 1.76 (bs, 6H), 1.89 (s, 3H), 1.95~1.96 (s, 9H), 1.98 (s, 3H), 3.36~3.38 (m, 1H), 3.43~3.46 (m, 3H), 3.59 (d, 1H, J = 8.4 Hz), 3.89~3.92 (m, 2H), 4.04~4.08 (m, 4H), 4.41 (d, 1H, J = 10.0 Hz), 4.60 (s, 2H), 4.84 (d, 1H, J = 10.0 Hz), 4.93 (d, 1H, J = 6.4 Hz), 5.04 (t, 1H, J = 7.2 Hz), 5.35 (d, 1H, J = 6.4 Hz), 5.57~5.61 (t, 1H, J = 7.2 Hz), 7.13~7.19 (m, 5H), 7.28~7.40 (m, 5H). LC / MS: M+-2 = 943.

[0109] Compound 41: 1H NMR (400 MHz, CDCl3): δ 1.21~1.35 (m, 8H), 1.45~1.62 (bs, 8H), 1.76 (bs, 6H), 1.90 (s, 3H), 1.95~2.22 (m, 12H), 3.43~3.46 (m, 4H), 3.60~3.71 (m, 1H), 3.94 (d, 1H), 4.04~4.12 (m, 4H), 4.20 (m, 1H), 4.55~4.59 (m, 1H), 4.62~4.70 (m, 2H), 4.84 (d, 1H, J = 10.0 Hz), 4.93 (d, 1H, J = 6.4 Hz), 5.30 (t, 1H, J = 7.2 Hz), 5.35 (m, 1H), 5.61 (t, 1H, J = 7.2 Hz), 7.13~7.19 (m, 5H), 7.28~7.40 (m, 5H). LC / MS: M+-2 = 1015.

[0110] Compound 42:1H NMR (400MHz, CDCl3):δ 1.76(s,6H), 1.90(s,3H), 1.95(s,3H), 1.98(s,6H), 2.01(s,3H), 3.43~3.49(m,3H), 3.62~ 3.64(m,1H), 3.72(s,3H), 3.91~3.94(m,1H), 4.07~4.21(m,5H), 4.42(d,1H,J=12.4Hz), 4.5 9(s,2H), 4.85(d,1H,J=12.4Hz), 5.05(t,1H,J=10.8Hz), 5.34~5.37(m,2H), 5.60(t,1H,J=1 0.8Hz), 6.69(d,2H,J=9.2Hz), 6.77(d,2H,J=9.2Hz), 7.11~7.21(m,5H), 7.29~7.42(m,5H). LC / MS:M+=986.

[0111] Synthesis of compound 15: Compound 15 was synthesized from compound 39 (0.5 g) by removing the NDMM group using hydrazine hydrate in HCl, followed by treatment with Ac2O to introduce the NHAc group. Finally, the -OAc group was removed by NaOCH3 / MeOH at room temperature to give compound 15 (22 mg white solid) as previously described [Mohamed RE et al, Carbohydrate research, 2001, 331, 129-142]. 1H NMR (400 MHz, CDCl3): δ 1 .98(s,6H), 3.43~3.49(m,3H), 3.62~3.64(m,1H), 3.72(s,3H), 3.91~3.94(m,1H), 4.23~4.42(m,3H), 4.62(m,4H), 5.90(d, 1H,J=10.8Hz), 6.42(d,1H,J=10.8Hz), 6.91(d,2H,J=8.4Hz), 7.12~7.21(m,5H), 7.29~7.42(m,5H), 8.06(d,2H,J=8.4Hz). LC / MS:M+=710.

[0112] Synthesis of compound-43: To a stirred suspension of D-glucosamine 29 (200 g, 0.93 mol) in pyridine was added acetic anhydride (720 mL, 7.4 mol). The reaction mixture was stirred for 12 h (monitored by TLC) and warmed to 60° C., and the reaction mixture was concentrated under reduced pressure. The residue was poured onto ice, extracted with chloroform (3×1 L), washed with 1 L of aqueous hydrochloric acid (3%), saturated sodium bicarbonate solution (1 L), distilled water (1 L), and dried over anhydrous sodium sulfate. The crude mixture 43 was carried on to the next step without further purification.

[0113] Synthesis of compound 44: To a solution of crude mixture 43 (30 g, 77.09 mmol) in THF at room temperature, methylamine in MeOH (2 M, 77 mL, 154.1 mmol) was slowly added and stirred at the same temperature for 12 h while monitoring by TLC. The reaction mixture was diluted with ethyl acetate (2 L), washed with water (3×1 L), brine (1 L), dried over Na2SO4 and evaporated. Compound 44 (20 g) was obtained.

[0114] Synthesis of compound-45: A mixture of compound 44 (20 g, 0.057 mol), CCl3CN (11 mL, 0.114 mol) and DBU (2.5 mL, 0.0014 mol) in dry CH2Cl2 was stirred at room temperature for 15-16 h. The reaction mixture was concentrated to give the crude product. The crude product was purified by silica gel chromatography using EtOAc (25-35%) in petroleum ether to give compound 45 (5 g). 1H NMR (400MHz, CDCl3):δ 1.91(s,3H), 1.93(s,3H), 2.01(s,3H), 2.07(s,3H), 3.93~4.01(m,1H), 3.98~4.03(dd,1H), 4.3 3~4.40(m,2H), 5.20(t,1H,J=9.2Hz), 5.73(t,1H,J=9.2Hz), 6.45(d,1H,J=9.2Hz), 8.67(s,1H).

[0115] Synthesis of compound-24: To a stirred suspension of compound 45 (2 g, 5.14 mmol) and 4-OH-TEMPOL (0.7 g, 4.11 mmol) in DCM, molecular sieve powder was added and stirred at room temperature for 2 h, to which triflic acid (0.11 g, 0.77 mmol) was added and stirred at room temperature for 4 h. The RM (reaction mixture) was distilled and purified by column chromatography eluting with 5% MeOH in DCM to give compound 24 (300 mg). 1H NMR (400MHz, CDCl3):δ 1.14(s,12H), 1.41~1.66(m,4H), 1.91(s,3H), 1.93(s,3H), 2.01(s,3H), 2.07(s,3H), 4.15~4.36(m,4H), 5.30(d,1H,J=9.2Hz), 5.73(t,1H,J=9.2Hz), 6.45(d,1H,J=9.2Hz). TLC-based :10% MeOH in DCM, Rf :0.3.

[0116] Synthesis of compound 25: To a stirred solution of compound 24 (0.3 g, 0.79 mmol) in MeOH at room temperature, NaOMe (0.04 g, 0.63 mmol) was added and stirred at the same temperature for 3-4 h. The reaction mixture was monitored by TLC, concentrated MeOH, and neutralized with 1M HCl in dioxane. The RM was Concentration and purification by column chromatography using 7% MeOH in DCM as eluent gave compound 25 (50 mg). 1H NMR (400 MHz, CDCl3): δ 1.14 (s, 12H), 1.41-1.66 (m, 4H), 1.93 (s, 3H), 4.15-4.36 (m, 4H), 5.30 (d, 1H, J = 9.2 Hz), 5.73 (t, 1H, J = 9.2 Hz), 6.45 (d, 1H, J = 9.2 Hz). LC / MS: M+ = 374. TLC system: 10% MeOH in DCM, Rf: 0.2. EXAMPLES

[0117] Topical / intravitreal preparations The following table represents exemplary ranges for topical or intravitreal ophthalmic compositions according to the present invention:

[0118] [Table 2] EXAMPLES

[0119] Injection The following table represents an exemplary range of intravenous (IV) compositions according to the invention: A compound of the invention is dissolved in a large volume of water (35° C.-40° C.) and the pH adjusted to 4.0-7.0 with hydrochloric acid or sodium hydroxide as necessary. The batch is then made up to volume with water and filtered through a sterile micropore filter into a sterile 10 mL amber glass vial (Type 1) and sealed with a sterile closure and seal.

[0120] [Table 3] EXAMPLES

[0121] The following table represents exemplary ranges of topical gel, lotion and spray compositions according to the present invention:

[0122] Gel formulation: The following table represents an exemplary range of gel compositions according to the present invention: Carbomer 934 is uniformly dispersed in approximately 40% of the total amount of water. Ammonia solution is gradually added to the dispersion with stirring to form a transparent gel. In a separate container, methylparaben is dissolved in propylene glycol, and then 10.0 g of Compound 15 is dispersed in this solution to form a homogeneous suspension. The suspension is gradually added to the gel with stirring to obtain a homogeneous white opaque gel.

[0123] [Table 4]

[0124] Cream or lotion formulations: The following table shows an exemplary range of cream or lotion compositions according to the present invention: Methylparaben is dissolved in about 80% of the total amount of propylene glycol. Poloxyl 2 cetyl ether is added to this solution while stirring. In a separate processing vessel, 20% propylene glycol, a portion of purified water and 10.0 g of compound 15 are mixed to form a uniform suspension. The suspension is gradually added to the first processing vessel with moderate stirring until a homogeneous, soft, white cream is obtained. The cream is passed through a colloid mill and the batch mass is brought to the target amount.

[0125] [Table 5]

[0126] Non-aerosol spray formulations: The following table shows an exemplary range of non-aerosol spray compositions according to the present invention: 5.00g of polyoxyl 10 oleyl ether is dissolved in 188.75g of castor oil with gentle stirring. 25.0g of compound 15 and 25.0g of zinc oxide are suspended in the slurry with moderate stirring, followed by 1.25g of fumed silica gel. The slurry is mixed under high shear until it is uniform and smooth, and packaged in a spray bottle.

[0127] The present invention and its embodiments have been described in detail. However, the scope of the present invention is not intended to be limited to the particular embodiments of the process, manufacture, composition of matter, compound, means, methods, and / or steps described herein. Various modifications, substitutions, and variations can be made to the disclosed materials without departing from the spirit and / or essential characteristics of the invention. Thus, one skilled in the art will readily appreciate from the disclosure that subsequent modifications, substitutions, and / or variations that perform substantially the same function or achieve substantially the same results as the embodiments described herein may be utilized in accordance with such embodiments related to the present invention. Therefore, it is intended that the following claims include within their scope modifications, substitutions, and variations of the process, manufacture, composition of matter, compound, means, methods, and / or steps disclosed herein.

[0128] [Table 6]

[0129] To the extent that the above description and accompanying drawings disclose any additional subject matter, the present invention is generally Each application is hereby incorporated by reference in its entirety and is hereby incorporated by reference in its entirety, and the right to file one or more applications claiming such additional inventions is reserved. References

[0001] Leon, Carlos G.; Tory, Rita; Jia, Jessica; Sivak, Olena; Wasan, Kishor M. a.Pharmaceutical Research (2008), 25(8), 1751-1761

[0002] Savva Athina; Roger Thierry From Frontiers in immunology (2013), 4387, Language: English, Database: MEDLINE

[0003] Cho, Y.; Wang, J. J.; Chew, E. Y.; Ferris, F. L.; Mitchell, P.; Chan, C.-C.; Tuo, J., Toll-like Receptor Polymorphisms and Age-Related Macular Degeneration: Replication in Three Case-Control Samples. Investigative Ophthalmology & Visual Science 2009, 50, (12), 5614-5618

[0004] Higgins, G. T.; Wang, J. H.; Dockery, P.; Cleary, P. E.; Redmond, H. P., Induction of angiogenic cytokine expression in cultured RPE by ingestion of oxidized photoreceptor outer segments. Invest Ophthalmol Vis Sci. 2003, 44(4):1775-82

[0005] Kaarniranta, K.; Salminen, A., Age-related macular degeneration: activation of innate immunity system via pattern recognition receptors. J Mol Med (Berl). 2009, 87(2):117-23

[0006] Elner, S. G.; Petty, H. R.; Elner, V. M.; Yoshida, A.; Bian, Z.-M.; Yang, D.; Kindezelskii, A. L., TLR4 mediates human retinal pigment epithelial endotoxin binding and cytokine expression. Transactions of the American Ophthalmological Society 2005, 103, 126-137

[0007] Yi, H.; Patel, A. K.; Sodhi, C. P.; Hackam, D. J.; Hackam, A. S., Novel Role for the Innate Immune Receptor Toll-Like Receptor 4 (TLR4) in the Regulation of the Wnt Signaling Pathway and Photoreceptor Apoptosis. PLoS One 2012, 7, (5), e36560

[0008] He, C.; Sun, Y.; Ren, X.; Lin, Q.; Hu, X.; Huang, X.; Su, S.-B.; Liu, Y.; Liu, X., Angiogenesis mediated by toll-like receptor 4 in ischemic neural tissue. Arterioscler Thromb Vasc Biol. 2013, 33(2):330-8

[0009] Huang, J.-D.; Amaral, J.; Lee, J. W.; Rodriguez, I. R., 7-Ketocholesterol-Induced Inflammation Signals Mostly through the TLR4 Receptor Both In Vitro and In Vivo. PLoS One 2014, 9, (7), e100985

[0010] CN 102475714

[0011] CN 101732338

[0012] US 20020022601

[0013] Hadwiger, Lee A.; Klosterman, S.; Chang, M.-M.; Friel, P.; Hosick, H. L., From Advances in Chitin Science (1997), 2, 102-109

[0014] EP 183556

[0015] Xu, Ke; Chen, Jun-quan Zhongguo Laonianxue Zazhi (2012), 32(24), 5478-5480

[0016] Wang, Jianyun; Chen, Yuanwei; Ding, Yulong; Shi, Guoqi; Wan, Changxiu, Applied Surface Science (2008), 255(2), 260-262

[0017] Xiong, Chuannan; Wu, Haige; Wei, Peng; Pan, Ma; Tuo, Yaqin; Kusakabe, Isao; Du, Yuguang, Carbohydrate Research (2009), 344(15), 1975-1983

[0018] CN102085212

[0019] Opal, S. M.; Laterre, P.; Francois, B.; et al., Effect of eritoran, an antagonist of md2-tlr4, on mortality in patients with severe sepsis: The access randomized trial. JAMA 2013, 309, 1154-1162

[0020] Wong, W. L.; Su, X.; Li, X.; Cheung, C. M. G.; Klein, R.; Cheng, C.-Y.; Wong, T. Y., Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The La ncet Global Health 2014, 2, e106-e116

[0021] Harrell, S. N.; Brandon, D. H., Retinopathy of Prematurity: The Disease Process, Classifications, Screening, Treatment, and Outcomes. Neonatal Network 2007, 26, 371-378

[0022] Cho, Y.; Wang, J. J.; Chew, E. Y.; Ferris, F. L.; Mitchell, P.; Chan, C.-C.; Tuo, J., Toll-like Receptor Polymorphisms and Age-Related Macular Degeneration: Replication in Three Case-Control Samples. Investigative Ophthalmology & Visual Science 2009, 50, 5614-5618

[0023] He, C.; Sun Y Fau - Ren, X.; Ren X Fau - Lin, Q.; Lin Q Fau - Hu, X.; Hu X Fau - Huang, X.; Huang X Fau - Su, S.-B.; Su Sb Fau - Liu, Y.; Liu Y Fau - Liu, X.; Liu, X., Angiogenesis mediated by toll-like receptor 4 in ischemic neural tissue

[0024] Xia, W.; Liu, P.; Zhang, J.; Chen, J., Biological activities of chitosan and chitooligosaccharides. Food Hydrocolloids 2011, 25, 170-179

[0025] Mosser, D. M., The many faces of macrophage activation. Journal of Leukocyte Biology 2003, 73, 209-212

[0026] Panda, S. K.; Kumar, S.; Tupperwar, N. C.; Vaidya, T.; George, A.; Rath, S.; Bal, V.; Ravindran, B., Chitohexaose Activates Macrophages by Alternate Pathway through TLR4 and Blocks Endotoxemia. PLoS Pathog 2012, 8, e1002717

[0027] Roger, T.; Froidevaux C Fau - Le Roy, D.; Le Roy D Fau - Reymond, M. K.; Reymond Mk Fau - Chanson, A.-L.; Chanson Al Fau - Mauri, D.; Mauri D Fau - Burns, K.; Burns K Fau - Riederer, B. M.; Riederer Bm Fau - Akira, S.; Akira S Fau - Calandra, T.; Calandra, T., Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4

[0028] Ceri, H.; Olson, M. E.; Stremick, C.; Read, R. R.; Morck, D.; Buret, A., The Calgary Biofilm Device: New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms. Journal of Clinical Microbiology 1999, 37, 1771-1776

[0029] Li, L.; Cheung, A.; Bayer, A. S.; Chen, L.; Abdelhady, W.; Kreiswirth, B. N.; Yeaman, M. R.; Xiong, Y. Q., The Global Regulon sarA Regulates beta-lactam Antibiotic Resistance In Methicillin-resistant Staphylococcus aureus (MRSA) In Vitro and In Endovascular Infections. The Journal of infectious diseases 2016

[0030] Archer, N. K.; Mazaitis, M. J.; Costerton, J. W.; Leid, J. G.; Powers, M. E.; Shirtliff, M. E., Staphylococcus aureus biofilms: Properties, regulation and roles in human disease. Virulence 2011, 2, 445-459

[0031] Hurdle, J. G.; Yendapally, R.; Sun, D.; Lee, R. E., Evaluation of Analogs of Reutericyclin as Prospective Candidates for Treatment of Staphylococcal Skin Infections. Antimicrobial Agents and Chemotherapy 2009, 53, 4028-4031

[0032] Hurdle, J. G.; Lee, R. B.; Budha, N. R.; Carson, E. I.; Qi, J.; Scherman, M. S.; Cho, S. H.; McNeil, M. R.; Lenaerts, A. J.; Franzblau, S. G.; Meibohm, B.; Lee, R. E., A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. Journal of Antimicrobial Chemotherapy 2008, 62, 1037-1045

[0033] Spilsbury, K.; Garrett, K. L.; Shen, W.-Y.; Constable, I. J.; Rakoczy, P. E., Overexpression of Vascular Endothelial Growth Factor (VEGF) in the Retinal Pigment Epithelium Leads to the Development of Choroidal Neovascularization. The American Journal of Pathology 2000, 157, 135-144

[0034] Betts, B. S.; Parvathaneni, K.; Yendluri, B. B.; Grigsby, J.; Tsin, A. T. C., Ginsenoside-Rb1 Induces ARPE-19 Proliferation and Reduces VEGF Release. ISRN Ophthalmology 2011, 2011, 184295

Claims

1. Formula (V) 【Chemistry 1】 (In the formula, n=1 to 5 R=H, C(O)CH 3 , benzyl (each R may be different from the others, except for benzyl when bonded to N). R 1 = H, substituted aryl (excluding o-hydroxyphenyl) or a pharma- ceutical composition for treating sepsis, comprising a compound of formula (I) or a pharma- ceutical acceptable salt thereof, 【Chemistry 2】 or 【Chemistry 3】 (Bn = benzyl) The pharmaceutical composition for treating sepsis,

2. 10. The composition of claim 1, formulated into a sterile injectable aqueous or oleaginous suspension, or a sterile topical gel, ointment or aqueous spray.

3. The composition of claim 1 further comprising at least one of an anti-inflammatory agent or an anti-bacterial agent.

4. 13. Use of the pharmaceutical composition of claim 1 for the manufacture of a medicament for treating sepsis, said use comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 1 to a subject in need thereof.

5. 5. The use according to claim 4, wherein the pharmaceutical composition comprises about 5.0 mg to about 100 mg of the compound of formula (V) or a pharma- ceutically acceptable salt thereof for a patient in need thereof, thereby treating said patient, or the pharmaceutical composition comprises about 10.0 mg to about 1000 mg of the compound of formula (V) or a pharma- ceutically acceptable salt thereof for a patient in need thereof, thereby treating said patient.

Citation Information

Patent Citations

  • Dermal drug for external use

    JP1992001115A

  • Novel TLR4 inhibitors for the treatment of human infectious and inflammatory disorders

    US20130281395A1

  • JPP7357364B

  • Methods of treating inflammation

    US20040214792A1